INVIMA Clinical Trial Approval Process in Colombia: Expert Protocol Review Hacks for Faster Ethics Clearance
Expert strategies for navigating INVIMA's clinical trial approval process, avoiding common protocol review pitfalls, and accelerating ethics clearance in Colombia.
March 30, 2026
13
min read
By
BioAccess Editorial Team
Colombia
INVIMA
clinical trials
ethics committee
regulatory
Latin America
medical devices
**Key Takeaways**
- • INVIMA approval can be achieved materially faster with optimized submission packages that pre-address reviewer concerns
- • Non-certified ethics committees are the #1 cause of downstream regulatory complications — use only INVIMA-certified CEIs
- • Colombia recruits 2x faster than the US for early-phase trials, with concentrated urban populations in Bogotá, Medellín, and Cali
- • Per-patient costs are 40-55% lower than US equivalents across most therapeutic areas
- • Colombia is bioaccess®'s #1 operating country with 15+ years of INVIMA experience and 30+ studies completed
**Who Is This For?**
This guide is for regulatory affairs managers, clinical operations directors, and MedTech/biopharma/radiopharma startup founders planning to submit a clinical trial application to INVIMA — particularly those running their first study in Colombia who need to avoid common pitfalls.
INVIMA Submission Roadmap
Colombia's Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) is the national regulatory authority responsible for clinical trial oversight. Understanding the INVIMA submission workflow is essential for planning realistic timelines and avoiding the delays that affect most first-time sponsors.
The INVIMA clinical trial approval process involves two parallel tracks: national regulatory authority review (INVIMA) and ethics committee review (CEI — Comité de Ética en Investigación). Both approvals are required before study initiation.
Required Documents and Expected Timelines
| Document | Preparation Time | Review Time | Tips |
|---|---|---|---|
| Protocol + amendments | 2-4 weeks | Part of INVIMA review | Include Spanish summary |
| Investigator's Brochure | 1-2 weeks | Part of INVIMA review | Complete preclinical section |
| Informed Consent Form | 1-2 weeks | CEI focus item | Culturally adapted, plain language |
| Risk Management File (ISO 14971) | 2-4 weeks | Part of INVIMA review | Critical for novel devices |
| Insurance Certificate | 1-2 weeks | Required by CEI | Colombia-specific policy required |
| INVIMA Application (Form) | 1 week | 4-8 months total | Pre-consultation recommended |
Protocol Review Red Flags from Real INVIMA Submissions
After reviewing hundreds of INVIMA submissions across 15+ years, bioaccess® has identified the top protocol review red flags that trigger reviewer queries and add 2-4 months to approval timelines:
Real ATM Study Pitfalls
- Incomplete risk management files: INVIMA reviewers expect a complete ISO 14971 risk management file for novel devices, not just a risk summary table
- Missing local laboratory reference ranges: Protocols referencing US or EU lab normal values without Colombian equivalents trigger queries
- Culturally inappropriate informed consent: Direct English-to-Spanish translations without cultural adaptation are flagged — Colombia requires plain-language ICFs accessible to diverse education levels
- Insufficient FIH risk-benefit justification: For novel devices, INVIMA expects explicit justification of why first-in-human risk is acceptable, including animal data summaries and comparator device safety profiles
- Missing Spanish preclinical summaries: While full dossiers can be in English, INVIMA requires Spanish-language summaries of key preclinical findings
**Pro Tip: Pre-Consultation Meeting**
bioaccess® recommends requesting an INVIMA pre-submission consultation (consulta previa) before formal application. This 30-60 minute meeting with INVIMA reviewers identifies potential concerns before they become formal queries — reducing review cycles by an average of 6-8 weeks.
Ethics Committee Hacks: Certified vs Non-Certified Sites
Why Committee Certification Matters
Colombia has both INVIMA-certified and non-certified institutional ethics committees (CEIs). This distinction is critically important and frequently misunderstood by international sponsors:
- INVIMA-certified CEIs: Have passed formal INVIMA audit and accreditation. Their approvals carry full regulatory weight and are recognized without additional conditions
- Non-certified CEIs: Can review studies but INVIMA may impose additional documentation requirements, request supplementary reviews, or delay final approval pending certification verification
- bioaccess® exclusively partners with INVIMA-certified ethics committees to eliminate certification-related delays
- Certification status should be verified at the time of submission — committees can lose certification between audit cycles
Ethics committee acceleration strategies:
- Submit to the CEI simultaneously with the INVIMA application — the reviews run in parallel, not sequentially
- Include a pre-formatted CEI evaluation checklist with your submission to accelerate the committee's review
- Schedule a pre-submission call with the CEI chair to discuss the study and identify potential concerns
- Provide the informed consent form in both clean and track-changes versions for easier committee review
Patient Recruitment Acceleration in Colombia
Colombia's patient recruitment speed is one of its strongest competitive advantages. For most early-phase device and drug studies, Colombia achieves 2x faster recruitment than the US. Key drivers include:
- Concentrated urban populations: Bogotá (8M), Medellín (3.5M), and Cali (2.5M) provide large recruitment pools within single metropolitan areas
- High patient willingness: Colombian patients show higher clinical trial participation rates than US/EU populations, particularly for innovative device therapies
- Physician-patient trust: Strong doctor-patient relationships in Colombia mean physician recommendations drive enrollment — bioaccess® leverages KOL referral networks
- Lower patient competition: Fewer competing clinical trials in Colombia means less patient fatigue and faster recruitment for individual studies
- Specialized disease registries: Many Colombian hospitals maintain disease-specific patient registries that enable targeted recruitment
Cost Savings: Colombia vs US Early-Phase Trials
| Cost Category | Colombia | United States | Savings |
|---|---|---|---|
| Per-patient cost | $15K-$25K | $30K-$55K | 40-55% |
| Ethics + regulatory | $15K-$30K | $50K-$150K | 50-70% |
| Site management (annual) | $40K-$80K | $100K-$250K | 50-65% |
| Monitoring (per visit) | $1.5K-$3K | $3K-$6K | 45-55% |
| Total FIH program (10 pts) | $350K-$600K | $700K-$1.5M | 45-55% |
Frequently Asked Questions
BA
bioaccess® · A CRO purpose-built exclusively for first-in-human clinical trials across Latin America. Colombia is bioaccess®'s #1 operating country with 30+ INVIMA-approved studies since 2010.
About bioaccess®
Colombia Overview
Ready to Start Your INVIMA Clinical Trial Application?
Colombia's combination of regulatory maturity, recruitment speed, cost efficiency, and bioaccess®'s 15+ years of INVIMA experience makes it one of Latin America's premier destinations for clinical trials. With optimized submission packages and the right operational partner, you can achieve INVIMA approval materially faster than industry averages.
Schedule a Strategy Call
Estimate Your Colombia Budget
Related resources:
- Clinical Trials in Colombia — /clinical-trials-colombia
- First-in-Human CRO Services — /first-in-human-cro
- FIH Medical Device Trial Chile — /blog/first-in-human-medical-device-trial-chile
- EFS CRO Latin America — /blog/early-feasibility-study-cro-latin-america